Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
about
Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patientsAntiangiogenic mechanisms and factors in breast cancer treatmentCurrent Management Strategies in Breast Cancer by Targeting Key Altered Molecular PlayersCirculating tumor cells in breast cancerAntiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsMMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.Developmental therapeutics for inflammatory breast cancer: Biology and translational directionsClinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Best management of locally advanced inoperable breast cancer.International study on inter-reader variability for circulating tumor cells in breast cancerChallenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast CancerPrecision medicine in breast cancer: reality or utopia?Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistanceA Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.Circulating tumor cells in newly diagnosed inflammatory breast cancer.Targeting angiogenesis in metastatic breast cancerA systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant ChemotherapyCirculating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer.The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatmentEmerging trends for radioimmunotherapy in solid tumorsCombined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade.Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study.Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer.The life, death, and attempted rebirth of bevacizumab in breast cancer.Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.Management of locally advanced breast cancer-perspectives and future directions.UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?Targeted adjuvant therapy in breast cancer.Circulating Tumor Cells as Cancer Biomarkers in the Clinic.Inflammatory breast cancer: A decade of experience.Adverse events of monoclonal antibodies used for cancer therapy.Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study.Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer.Bevacizumab in HER2-negative inflammatory breast cancer.The Third International Inflammatory Breast Cancer Conference.IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model.
P2860
Q21284707-6FB3779A-C2C7-4939-A3A8-1A62208C5993Q26751226-64924518-67BC-4091-AAFE-3318AE850D4CQ26765877-593071D9-2188-46EB-9B39-6D521202D25FQ26774808-27286F2F-F92B-485B-B1E4-C8C6D4CB2505Q26822432-43847099-2504-4B97-97FC-DA5B1DD84179Q27853354-5B1C0640-5A05-4697-9351-F37018042A63Q28075322-4801FDE3-E352-4017-AEB7-CB3542B809B7Q31157714-0C995354-A92E-4A50-8B1F-6A4352E7C99FQ33699040-BC09C7BA-B749-49C1-AF6C-E78F2D50E3F3Q33738688-98C07B5E-9C69-47B7-84EA-B042ACCE7288Q33760216-77E862ED-F63A-422D-9B1E-02160F62DC7AQ33809114-EBD8F2F9-8510-4331-9653-1EA4CC3B23A4Q34355748-AFABE189-8F8A-4712-868B-A63D27801050Q35001280-05EE6C49-B6E8-486E-8804-B67D81558525Q35052773-C8A586EC-78F3-47D5-8B0F-7D3EAC7109BBQ36182795-44B3ABEC-6E75-4B41-8333-705D6695A08AQ36215991-93A29BC5-85F5-4AEB-93E1-8967BA3CCD76Q36693275-A44B247D-17FE-47C1-BC13-3C96BB5E2461Q36848095-3D606C9F-1B36-46FE-AA06-420BB50E0FC4Q36865945-0EE371FD-9567-41B9-9F54-6D98400DEC85Q37185872-BC4036F2-5638-46DD-A751-7412E7A46A8DQ37222795-46913FBD-23C5-4B8C-B592-5D64AB8A612DQ37361541-ABDBCD86-BB71-4D68-ACB1-4F2F329DA947Q37427956-F62EEFAC-A4E0-4C02-B10E-310B9457AE20Q37554911-CF0DC9A6-C404-419C-9B5B-FDECC3996951Q38070396-FE6EA75A-6335-4B16-88E4-8C6299C33A32Q38160648-0CF1EA87-F1E4-414A-B81F-B62489C2311FQ38245841-D6556A3A-401D-4A49-8EA8-0451A32CCD6BQ38350939-5CBA968D-120F-47ED-B581-56F66C4AA601Q38412031-A1C681E7-A44E-43B0-A13D-ECE04A62B67BQ38683638-3CE5CC26-3EC2-4EB5-BB0C-7A0375759174Q38980703-4E6CE98E-5172-406F-B88B-FDC48A20EC7CQ39339875-E7DDAF01-4552-4BE0-B152-3AEB2A463860Q39980598-D15F8146-BD4B-4C29-8A2D-34D07A81451CQ40812370-2FE26FA3-65D9-4BA2-8767-9D4BD9662E58Q41094757-3C60744A-ADCB-44E1-ACF2-BE2FFB26DC8EQ42069779-5BEDA96A-2C8D-4A0D-B6E1-69B43ABFF0A2Q42330451-67CB139C-116F-47DB-BCAA-4DE85726D317Q42369599-37C654C3-2220-42F6-8E19-764E06583EFDQ42478176-6F0B797D-D66A-48CF-B956-79A59486785F
P2860
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neoadjuvant bevacizumab, trast ...... bel, single-arm phase 2 study.
@en
Neoadjuvant bevacizumab, trast ...... bel, single-arm phase 2 study.
@nl
type
label
Neoadjuvant bevacizumab, trast ...... bel, single-arm phase 2 study.
@en
Neoadjuvant bevacizumab, trast ...... bel, single-arm phase 2 study.
@nl
prefLabel
Neoadjuvant bevacizumab, trast ...... bel, single-arm phase 2 study.
@en
Neoadjuvant bevacizumab, trast ...... bel, single-arm phase 2 study.
@nl
P2093
P50
P921
P1433
P1476
Neoadjuvant bevacizumab, trast ...... bel, single-arm phase 2 study.
@en
P2093
Florence Lerebours
Henri Roché
Jean-Marc Ferrero
Jean-Yves Pierga
Maria Pavlyuk
Mario Campone
Sandrine Kraemer
Thierry Delozier
Thierry Petit
Thomas Bachelot
P304
P356
10.1016/S1470-2045(12)70049-9
P577
2012-02-28T00:00:00Z